.webp)
JANESVILLE, Wis., Aug. 27, 2019 – SHINE Medical Technologies LLC today announced that its team for the annual Bert Blain Memorial Heart Walk in Janesville last weekend exceeded its fundraising goal by 40 percent. The SHINE team’s goal was $6,000 and it raised more than $8,400 to support the American Heart Association’s mission of reducing disability and death caused by heart disease and stroke.
This is the third year that SHINE has participated in the local Heart Walk, which brings together hundreds from the Janesville community to raise money for local research and educational programs about heart disease and stroke in Wisconsin. The SHINE team has nearly doubled its funds raised each walk since 2017, when it began participating. The team has a three-year fundraising total of more than $15,000.
“SHINE employees, friends and family members are extremely proud to support and participate in the Annual Bert Blain Memorial Heart Walk,” said Cheryl Peterson, community and employee engagement manager at SHINE. “We work hard to give back to the Janesville community that has supported SHINE so actively. We are grateful to participate in this longtime Janesville event because it rallies the community around awareness and prevention of heart disease, a critical public health problem that accounts for one in three deaths in the United States.”
Ms. Peterson led the SHINE team, 27 of whom participated in the walk. SHINE prioritizes opportunities for community engagement that complement its mission, including those that work to eradicate heart disease and cancer. This year marked the 26th anniversary of the Bert Blain Memorial Heart Walk.
Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium 99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and to stage cases of cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce a variety of medical isotopes, including Mo‑99. Roughly one percent of all Mo-99 in the world decays every hour, meaning it must be produced continuously. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!
Media Contact: info@shinefusion.com
